At the 28th edition of the Conference on Human Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented amongst others, abstracts around some of the latest findings and progress being made on HIV/AIDS research.
ViiV Abstracts for CROI 2021
Inflammatory and atherogenesis markers 148 weeks post-switch to DTG + RPV in SWORD-1/-2
Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 96 weeks: subgroup analyses from the TANGO study
Durable efficacy of DTG + 3TC in GEMINI-1&-2: year 3 subgroup analyses
Association between newer antiretrovirals and increase in body mass index in RESPOND
Association between integrase inhibitors (INSTIs) and cardiovascular disease
Cabotegravir PPK simulation to inform Q2M strategies following dosing interruptions
Weight and lipid changes in phase 3 cabotegravir and rilpivirine long-acting trials
Long-acting cabotegravir + rilpivirine in older adults: pooled phase 3 Week 48 results
Week 96 efficacy and safety of cabotegravir + rilpivirine every 2 months: ATLAS-2M
Renal/bone outcomes after long-acting cabotegravir + rilpivirine in ATLAS + ATLAS-2M
PopPK modelling of Q2M IM RPV LA for managing dosing interruptions in HIV-1 patients
Reduced susceptibility to temsavir is not linked to IBA or MVC resistance
Randomised Controlled Trial (RCT) of an online mental health intervention among older PLWH during COVID-19 pandemic
You are about to leave a ViiV Healthcare website. By clicking this link, you will be taken to a website that is independent from ViiV Healthcare. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site.
This is an archived press release which may not reflect current medical knowledge and should not be used as a source of information on the present label, safety data or efficacy data for ViiV Healthcare products and/or their uses. Please refer to your nationally approved label or summary of product characteristics for up-to-date product information.